In a report released today, Jason McCarthy from Maxim Group maintained a Hold rating on IntelliPharmaCeutics International (NASDAQ: IPCI). The company’s shares opened today at $0.47, close to its 52-week low of $0.32.
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 9.5% and a 44.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
IntelliPharmaCeutics International has an analyst consensus of Moderate Buy, with a price target consensus of $2.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.92 and a one-year low of $0.32. Currently, IntelliPharmaCeutics International has an average volume of 279.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.
